Published in Hepatitis Weekly, July 8th, 2002
The new name, Idenix, is intended to reflect the application of its drug discovery expertise and development experience in the areas of hepatitis B, hepatitis C and HIV and the potential application of this expertise and experience to the treatment of other infectious diseases.
Idenix is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.